Sanofi India Sees Growth in Key Therapies, Despite Profit Dip Amid Transformation Costs

Sanofi India has reported a robust revenue increase for the quarter ending December 2024, driven by strong performance in its cardiovascular (CV) and central nervous system (CNS) therapies, bolstered by successful partnerships. However, the company's net profit experienced a significant decline due to strategic investments and one-time transformation costs. According to Rodolfo Hrosz, Managing Director of Sanofi India, the company's strategic partnerships are yielding positive results, meeting expectations and indicating substantial growth potential in the coming quarters. The company's revenue for the quarter reached Rs 514.9 crore, marking a 9.7 percent year-on-year increase from Rs 469.2 crore in the same period last year. Sanofi India attributed this growth to momentum across key therapeutic segments and successful product launches. Operational performance also showed improvement, with EBITDA rising by 18.8 percent to Rs 118.3 crore from Rs 99.6 crore in the corresponding quarter. The operating margin expanded to 23 percent, up from 21.2 percent, driven by cost optimization and favorable product mix. Despite these operational gains, Sanofi India's net profit fell sharply by 33.7 percent to Rs 91.3 crore, compared to Rs 137.7 crore in the same quarter of the previous year. This contraction was primarily due to increased expenses related to strategic initiatives, product launches, and one-time costs associated with the company's ongoing transformation and expansion efforts.